Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones01-06

DJ Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Charles River Laboratories International Inc. $(CRL)$ advanced 2.01% to $189.54 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index rising 0.55% to 5,975.38 and the Dow Jones Industrial Average falling 0.06% to 42,706.56.

This was the stock's second consecutive day of gains.

Charles River Laboratories International Inc. closed $85.46 below its 52-week high ($275.00), which the company reached on March 8th.

The stock outperformed some of its competitors Monday, as Labcorp Holdings Inc. $(LH)$ rose 0.34% to $229.92 and Alnylam Pharmaceuticals Inc. $(ALNY)$ fell 0.48% to $233.15.

Trading volume (652,113) remained 15,132 below its 50-day average volume of 667,245.

Data source: Dow Jones Market Data, FactSet. Data compiled January 6, 2025.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

January 06, 2025 17:26 ET (22:26 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment